Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Stabilized Prefusion F Subunit Vaccine (RSVpreF) Among Older Adults in Ireland
Author(s)
Marion Fahey, MSc1, Leah Russell, BSc, MSc1, Ahuva Averin, MPP2, Reece Grindley, MSc3, Diana Mendes, MSc, PhD4.
1Pfizer, Dublin, Ireland, 2Avalere Health, Boston, MA, USA, 3Avalere Health, London, United Kingdom, 4Pfizer Ltd., Tadworth, United Kingdom.
1Pfizer, Dublin, Ireland, 2Avalere Health, Boston, MA, USA, 3Avalere Health, London, United Kingdom, 4Pfizer Ltd., Tadworth, United Kingdom.
OBJECTIVES: Evaluate the cost-effectiveness of RSVpreF vaccination among adults aged ≥65 years in Ireland.
METHODS: The cost-effectiveness of RSVpreF for prevention of RSV-LRTD among adults was explored using a static cohort model. Model inputs were estimated largely from published Ireland-specific data. Clinical outcomes included RSV-LRTD cases and attributable deaths, life-years (LYs) and quality-adjusted LYs (QALYs); economic costs included direct medical care and vaccination costs. Four populations were modelled: adults aged 65-99 years (y), at-risk adults aged 65-99y, adults aged 75-99y, and at-risk adults aged 75-99y. Risk conditions included chronic medical or immunocompromising conditions.
RESULTS: Among adults aged 65-99y, RSVpreF prevented 24,613 RSV-LRTD cases (5,310 hospitalizations) and 605 associated deaths. Reduction in medical care costs was €24M, vaccination costs were €126M, thus total costs were €102M and the incremental cost-effectiveness ratio (ICER) was €53,239/QALY. In the subgroup at-risk aged 65-99y, RSVpreF prevented 19,191 RSV-LRTD cases (4,973 hospitalizations) and 574 deaths. Overall costs were €49M (medical: -€22M; vaccination: €72M) and the ICER was €28,058/QALY.
Limiting vaccination to adults aged 75-99y, RSVpreF prevented 13,759 RSV-LRTD cases (3,256 hospitalizations) and 493 deaths, reducing medical care costs by €15M. Total vaccination costs were €61M, thus overall costs were €46M and the ICER was €32,940/QALY. In the subgroup at-risk aged 75-99y, RSVpreF prevented 11,410 RSV-LRTD cases (3,082 hospitalizations) and 469 deaths; overall costs were €24M (medical: -€14M; vaccination: €38M) and ICER was €18,965/QALY.
CONCLUSIONS: ICERs were all near or below the typical €45,000/QALY willingness-to-pay threshold. While all strategies evaluated would reduce the clinical and economic burden of RSV among older adults in Ireland, findings suggest RSVpreF vaccination for all aged ≥65y would have the greatest impact on the burden of RSV.
METHODS: The cost-effectiveness of RSVpreF for prevention of RSV-LRTD among adults was explored using a static cohort model. Model inputs were estimated largely from published Ireland-specific data. Clinical outcomes included RSV-LRTD cases and attributable deaths, life-years (LYs) and quality-adjusted LYs (QALYs); economic costs included direct medical care and vaccination costs. Four populations were modelled: adults aged 65-99 years (y), at-risk adults aged 65-99y, adults aged 75-99y, and at-risk adults aged 75-99y. Risk conditions included chronic medical or immunocompromising conditions.
RESULTS: Among adults aged 65-99y, RSVpreF prevented 24,613 RSV-LRTD cases (5,310 hospitalizations) and 605 associated deaths. Reduction in medical care costs was €24M, vaccination costs were €126M, thus total costs were €102M and the incremental cost-effectiveness ratio (ICER) was €53,239/QALY. In the subgroup at-risk aged 65-99y, RSVpreF prevented 19,191 RSV-LRTD cases (4,973 hospitalizations) and 574 deaths. Overall costs were €49M (medical: -€22M; vaccination: €72M) and the ICER was €28,058/QALY.
Limiting vaccination to adults aged 75-99y, RSVpreF prevented 13,759 RSV-LRTD cases (3,256 hospitalizations) and 493 deaths, reducing medical care costs by €15M. Total vaccination costs were €61M, thus overall costs were €46M and the ICER was €32,940/QALY. In the subgroup at-risk aged 75-99y, RSVpreF prevented 11,410 RSV-LRTD cases (3,082 hospitalizations) and 469 deaths; overall costs were €24M (medical: -€14M; vaccination: €38M) and ICER was €18,965/QALY.
CONCLUSIONS: ICERs were all near or below the typical €45,000/QALY willingness-to-pay threshold. While all strategies evaluated would reduce the clinical and economic burden of RSV among older adults in Ireland, findings suggest RSVpreF vaccination for all aged ≥65y would have the greatest impact on the burden of RSV.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE237
Topic
Economic Evaluation, Epidemiology & Public Health, Health Policy & Regulatory
Disease
Vaccines